MedTrace Logo

CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

NCT06816823 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-04

No results posted yet for this study

Summary

This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.

Conditions

Interventions

BIOLOGICAL

CL-NK-001

Dose level 1 (5 × 10\^8 cells); dose level 2 (15 × 10\^8 cells); dose level 3 (30 × 10\^8 cells); additional dose levels (investigator's discretion).

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhuan Liao, MD PhD · Changhai Hospital

  • Xuetao Cao, MD PhD · National Key Laboratory of Immunity & Inflammation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06816823 on ClinicalTrials.gov